{"groups":[{"description":"Supplied in blinded fashion as 20 and 40 mg powder in vials and 2 mL vehicle in ampoule (for reconstitution) for intramuscular administration every 28 days","id":"FG000","title":"Pasireotide LAR 40 mg"},{"description":"Supplied in blinded fashion as 20 and 40 mg powder in vials and 2 mL vehicle in ampoule (for reconstitution) for intramuscular administration every 28 days","id":"FG001","title":"Pasireotide LAR 60 mg"},{"description":"Open label octreotide LAR 30 mg or lanreotide ATG 120 mg supplied either locally or from designated depot. Administered intramuscular every 28 days","id":"FG002","title":"Control Arm (Octreotide or Lanreotide)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"0"}],"type":"Adverse Event-CORE"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"2"}],"type":"Withdrawal by Subject-CORE"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}],"type":"Administrative problems-CORE"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}],"type":"Protocol Violation-CORE"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"7"}],"type":"Adverse Event-Extension"},{"reasons":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"13"}],"type":"Lack of Efficacy-Extension"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"8"}],"type":"Withdrawal by Subject-Extension"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}],"type":"Lost to Follow Up-Extension"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"}],"type":"Administrative problems-Extension"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"Death-Extension"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}],"type":"Protocol Violation-Extension"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"2"}],"type":"Did not enter extension"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}],"type":"Did not receive treatment in extension"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"65"},{"groupId":"FG001","numSubjects":"65"},{"groupId":"FG002","numSubjects":"68"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"}],"type":"Not Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"63"},{"groupId":"FG001","numSubjects":"63"},{"groupId":"FG002","numSubjects":"67"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"59"},{"groupId":"FG001","numSubjects":"57"},{"groupId":"FG002","numSubjects":"65"}],"type":"Completed 24-Week Core Phase"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"2"}],"type":"Not Continuing Into Extension"},{"achievements":[{"groupId":"FG000","numSubjects":"57"},{"groupId":"FG001","numSubjects":"54"},{"groupId":"FG002","numSubjects":"63"}],"type":"Continuing Into Extension"},{"achievements":[{"comment":"2 patients never received drug.","groupId":"FG000","numSubjects":"63"},{"comment":"2 patients never received drug. 1 patient had no post baseline safety assement.","groupId":"FG001","numSubjects":"62"},{"comment":"2 patients never received drug.","groupId":"FG002","numSubjects":"66"}],"type":"Safety Set - CORE"},{"achievements":[{"groupId":"FG000","numSubjects":"57"},{"groupId":"FG001","numSubjects":"54"},{"comment":"1 patient did not receive study treatment","groupId":"FG002","numSubjects":"62"}],"type":"Safety Set - Extension"},{"achievements":[{"groupId":"FG000","numSubjects":"28"},{"groupId":"FG001","numSubjects":"25"},{"groupId":"FG002","numSubjects":"34"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"37"},{"groupId":"FG001","numSubjects":"40"},{"groupId":"FG002","numSubjects":"34"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"One hundred ninety-eight patients were randomized and 5 patients in CORE and 1 patient in extension did not receive any study treatment"}